The Lancet Series on Alzheimer's Disease 1

New landscape of the diagnosis of Alzheimer's disease

Giovanni B Frisoni, Oskar Hansson, Emma Nichols, Valentina Garibotto, Suzanne E Schindler, Wiesje M van der Flier, Frank Jessen, Nicolas Villain, Eider M Arenaza-Urquijo, Lucia Crivelli, Juan Fortea, Lea T Grinberg, Zahinoor Ismail, Satoshi Minoshima, Rik Ossenkoppele, Henrik Zetterberg, Ronald C Petersen, Bruno Dubois

Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis—a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide.

Lancet 2025; 406: 1389–407

Published Online September 22, 2025 https://doi.org/10.1016/S0140-6736(25)01294-2

This is the first in a Series of three papers about the new clinical landscape in Alzheimer's disease. All papers in the Series are available at https://www.thelancet.com/series-do/alzheimers-disease

Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva, Geneva, Switzerland (Prof G B Frisoni MD); **Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Malmö, Sweden** (Prof O Hansson MD*); **Memory Clinic, Skåne University Hospital, Malmö, Sweden** (Prof O Hansson); **Center for Economic and Social Research, University of Southern California, Los Angeles, CA, USA** (E Nichols PhD); **Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland** (V Garibotto MD); **Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland** (V Garibotto); **CIBM Center for Biomedical Imaging, Geneva, Switzerland** (V Garibotto); **Department of Neurology, Washington University School of Medicine, St Louis, MO, USA** (S E Schindler MD); **Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, Netherlands** (Prof W M van der Flier PhD); **Amsterdam Neuroscience-Neurodegeneration, Amsterdam, Netherlands** (Prof W M van der Flier); **Epidemiology and Data Science, Vrije Universiteit**

Introduction

What is Alzheimer's disease? Depending on who is asked, the answers vary, even among doctors and specialists. The definition of Alzheimer's disease is in dynamic evolution in the expert community, and unanimity has not yet been reached. For all practical purposes, Alzheimer's disease in clinical practice consists of cognitive impairment associated with biomarker evidence of its neuropathological hallmarks: β-amyloid plaques composed of aggregated β-amyloid, and neurofibrillary tangles composed of aggregated tau.[1] Different views on the definition of Alzheimer's disease are addressed in the last paper of this Series.[2] The diagnostic approach and patient journey that we describe in this paper are typical of many memory clinics in Europe and elsewhere[3] and are anchored to the clinical phenotype of a middle-aged or older patient with a history of progressive cognitive decline, sometimes accompanied by behavioural changes, neurological signs, and decreased function in everyday activities. Impairment on cognitive tests, particularly tests of episodic memory, and medial temporal atrophy patterns identified via structural brain imaging might support a clinical–radiological syndromic diagnosis of Alzheimer's disease, but are non-specific as they are shared by other neuropathologies. By contrast, molecular biomarkers, including PET, cerebrospinal fluid (CSF), and blood tests, can specifically mark the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles, which are characteristic of Alzheimer's disease, allowing for a clinical–biological diagnosis. These biomarkers enable assessment of neuropathological evidence in vivo, and when used in clinical practice, allow for increased accuracy (90–95%, compared with 60–70% of the traditional purely clinical approach)[4,5] and earlier diagnosis.[6]

It should be acknowledged that frequently, Alzheimer's disease is diagnosed based on clinical investigations and structural imaging only—ie, without biomarker confirmation. However, this is already changing as Alzheimer's disease-specific biological drugs require confirmation of β-amyloid pathology before treatment initiation.[7] At the time of the publishing of this review, the anti-amyloid monoclonal antibodies donanemab and lecanemab[8,9] are approved in an increasing number of countries, including the EU, the USA, the UK, China, Japan, South Korea, Hong Kong, United Arab Emirates, and Israel.

This Series paper on the diagnosis of Alzheimer's disease only considers biomarkers that are currently

Search strategy and selection criteria

We conducted a review of published articles with special focus given towards the past 5 years, since Jan 1, 2020, and up to including March 1, 2025, on the PubMed, Embase, Scopus, and Cochrane databases. The search was restricted to studies published in English with different combinations of the following keywords and medical subject heading terms in PubMed (MeSH) and Embase (Emtree): "Alzheimer's disease", "cognitive impairment", "dementia", "epidemiology", "incidence", "prevalence", "risk factor", "protective factor", "cognitive ageing", "biomarker", "APOE", "patient journey", "workflow", "algorithm", "taxonomy", "mild cognitive impairment", "subjective cognitive decline", "MRI", "PET", "CSF", "amyloid", "tau", "neurodegeneration". We prioritised the most robust evidence from clinical trials, systematic reviews, meta-analyses, and pooled studies. We also reviewed guidelines and position statements from the same period on the diagnosis of Alzheimer's disease, cognitive impairment, and dementia.

Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands (Prof W M van der Flier); German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany (Prof F Jessen MD); Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany (Prof F Jessen); Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany (Prof F Jessen); Assistance Publique–Hôpitaux de Paris Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France (N Villain MD); Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau (ICM), Paris, France (N Villain); Environment and Health Over the Life Course Programme, Climate, Air Pollution, Nature and Urban Health Programme, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain (E M Arenaza-Urquijo PhD); University of Pompeu Fabra, Barcelona, Spain (E M Arenaza-Urquijo); Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina (L Crivelli PhD); Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau, Barcelona, Spain (J Fortea MD); Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Madrid, Spain (J Fortea); Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain (J Fortea); Departments of Neurology and Pathology, The University of California San Francisco, San Francisco, CA, USA (Prof L T Grinberg MD); Global Brain Health Institute, The University of California San Francisco, San Francisco, CA, USA (Prof L T Grinberg); Department of Pathology, University of Sao Paulo Medical School, São Paulo, Brazil (Prof L T Grinberg); Department of Psychiatry, University of Calgary, Calgary, AB, Canada (Prof Z Ismail MD); Department of Radiology,

Glossary of terms

Alzheimer's Association Workgroup 2024 Revised Criteria
An integrated biological and clinical staging scheme with six clinical stages (graphically represented in left-to-right columns) and 4 biological stages (top-to-bottom rows). Biological Alzheimer's disease stage and clinical severity are related, but do not travel in lockstep. The typical or average relationship between biology and symptoms can be envisioned as moving along an upper left to lower right diagonal, following the steps of the amyloid cascade (from A–T– to A+T– to A+T+ in the medial temporal lobe, A+T+ with moderate neocortical burden, A+T+ with high neocortical burden. A=β-amyloid, and T=tau pathology). The criteria are conceptual and await validation.

Alzheimer's disease
There is no unanimity on the epistemological definition of Alzheimer's disease, reflected in sets of different diagnostic criteria (Alzheimer's Association Workgroup 2024 Revised Criteria and International Working Group 2024 diagnostic criteria). Disagreements extend to the existence of presymptomatic or preclinical Alzheimer's disease and the interpretation of Alzheimer's disease biomarker positivity in the absence of objective cognitive impairment or deterioration. However, for all practical purposes in clinical practice, Alzheimer's disease can be operationalised as cognitive impairment due to Alzheimer's disease pathology, evolving in stages of increasing cognitive and functional severity.

Alzheimer's pathology
Alzheimer's disease pathology or Alzheimer's disease neuropathological changes consist of the cortical deposition of aggregates of β-amyloid and hyperphosphorylated tau proteins.

Amyloid-targeting therapy
Pharmacological products aimed to decrease the load of aggregated β-amyloid in the brain or prevent aggregation, such as monoclonal antibodies directed towards different forms of aggregated or soluble amyloid. Two of these (lecanemab and donanemab) have been found effective in registration phase 3 trials at reducing cognitive progression by 27% to 39% in patients with Alzheimer's disease operationalised as cognitive impairment and β-amyloid pathology. Tau biomarkers are also ameliorated. Lecanemab and donanemab are approved for clinical use in the USA and other countries.

Biomarker
An objectively measurable substance, characteristic, or other parameter of a biological process that enables assessment of disease risk or prognosis and provides guidance for diagnosis or monitoring of treatment.

Braak stages
In Alzheimer's disease, a method to classify the progressive degree of neurofibrillary tangle involvement due to tau pathology. Stages I and II: confined mainly to the transentorhinal region of the brain. Stages III and IV: additional involvement of limbic regions such as the hippocampus. Stages V and VI: additional extensive neocortical involvement.

Cognitive disorders
All conditions that can cause cognitive impairment. These include neurodegenerative conditions such as Alzheimer's disease, but also vascular disease, traumatic brain injury, substance use, infections, disturbances of cerebrospinal fluid dynamics, psychiatric conditions, secondary or reversible cognitive disorders, and more. DSM-5 refers to "neurocognitive disorders" to differentiate the cognitive impairment of psychoses. We believe that the "neuro" prefix does not add meaningful information as, by definition, the brain is the organ responsible for all cognitive disorders.

Cognitive impairment
Problems with thinking, learning, remembering, using judgment, and making decisions that cannot be accounted for by age alone. In the differential diagnosis of cognitive disorders, it is used to infer change from a normal aging trajectory to an abnormal trajectory of decline. In highly educated or performant patients still scoring in the normal range of cognitive tests, clinical judgement can occasionally help identifying those on a trajectory of cognitive decline based on a clear history of progressive and consistent decline.

Delirium
A syndrome of acute confusion due to the direct physiological consequence of medical conditions, effects of psychoactive substances, acute brain diseases, or multiple causes on brain functioning. It often develops on a brain weakened by age-associated or neurodegeneration-associated pathology and usually develops over the course of hours to days with disturbances in attention, awareness, and higher-order cognition. Other neuropsychiatric disturbances are often associated, such as changes in psychomotor activity (eg, hyperactive, hypoactive, or mixed level of activity), disrupted sleep–wake cycle, emotional disturbances, altered state of consciousness, and perceptual disturbances (eg, hallucinations and delusions).

Dementia
A syndrome referring to acquired cognitive impairment affecting disability on daily activities. The term is largely regarded as stigmatising, of limited clinical usefulness (it fails to capture cognitive impairment with no loss of function), and imprecise (singular dementia denotes the syndrome, and plural dementias the diseases and conditions underlying the syndrome). For this reason, while acknowledging that the term is widely used in neurology, psychiatry, and geriatrics, we endorse the terms cognitive impairment and cognitive disorders (see entry in this table). Major neurocognitive disorder is the synonym for dementia in DSM-5.

(Continues on next page)

(Glossary continued from previous page)

International Working Group 2024 diagnostic criteria
Developed for clinical practice and research, the criteria postulate that Alzheimer's disease is a clinical–biological construct consisting of the association of Alzheimer's pathology (brain amyloidosis and tauopathy) with cognitive impairment of specific profiles. Presymptomatic are cognitively unimpaired people who are carriers of fully penetrant autosomal dominant monogenic Alzheimer's disease mutations. Alzheimer's pathology in the absence of cognitive impairment defines the asymptomatic at-risk individuals.

Lewy body disease
A spectrum of conditions due to the accumulation in the central and autonomic nervous system of Lewy bodies and Lewy neurites, whose primary structural component is α-synuclein. The spectrum includes Parkinson's disease (main cerebral affected structure is the substantia nigra), dementia with Lewy bodies (early involvement of the neocortex), and Parkinson's disease dementia (early involvement of the substantia nigra and later of the neocortex).

Mild cognitive impairment (MCI)
A syndrome referring to acquired and progressive cognitive impairment. The person may be slower and less efficient but can still function independently. In older age, it is commonly associated with neuropathology (eg, Alzheimer's disease), but it could be due to anything, including physical and psychiatric conditions. Mild neurocognitive disorder is the synonym to MCI in DSM-5.

Proteinopathies
Refers to certain proteins whose three-dimensional folding conformation becomes abnormal and disrupts cellular function. In Alzheimer's disease and related neurodegenerative diseases, the most frequent are β-amyloid and 3R-4R hyperphosphorylated tau (typical of Alzheimer's disease), α-synuclein (Parkinson's disease, dementia with Lewy bodies, and Parkinson's dementia), TAR DNA-binding protein-43 (TDP-43, in some forms of frontotemporal lobar degeneration), 4R hyperphosphorylated tau (typical of progressive supranuclear palsy and corticobasal degeneration), polyglutamine (Huntington's disease), and superoxide dismutase-1 (SOD1, in some forms of amyotrophic lateral sclerosis).

Staging
In Alzheimer's disease and the dementias in general, staging consists of assigning a degree of severity to the main clinical dimensions of the disease: cognitive, behavioural and psychiatric, functional, and motor or other neurological symptoms. Each should be rated as none, minimal, mild, moderate, or severe. For cognitive or functional staging, the Clinical Dementia Rating Scale is largely used.

Subjective cognitive decline (SCD)
A clinical construct referring to complaints of progressive cognitive problems with formal cognitive testing revealing unimpaired performance. SCD plus refers to certain features of SCD, which increase the likelihood that this condition is related to Alzheimer's disease pathology and that there is a higher risk of objective cognitive decline in the future. The currently proposed SCD plus criteria are: subjective decline in memory irrespective of function in other cognitive domains, onset of SCD within the past 5 years, onset of SCD at 60 years and older, concern (worry) associated with SCD, persistence of SCD over time, seeking of medical help, and confirmation of cognitive decline by an observer.

Worried well
Individuals who do not experience SCD themselves but are concerned about cognitive deterioration or Alzheimer's disease in the future. The label is controversial in the literature as it might lead to genuine concerns or pathology being dismissed.

clinically available or expected to be clinically available within the next year. Biomarkers of β-amyloid plaques and neurofibrillary tangles include PET tracers with high affinity for β-amyloid plaques or pathological tau inclusions in the neocortex,[10] and concentrations or ratios of β-amyloid peptides (Aβ42 and Aβ40) and tau species (including phosphorylated-tau181 [p-tau181]) in the CSF.[11–13] Additionally, some blood tests (p-tau217) reflect the presence of β-amyloid plaques and neurofibrillary tangles, and are now clinically available from several companies in the USA and an increasing number of other countries, but are not yet available globally. Biomarkers of neurodegeneration in Alzheimer's disease include decreased hippocampal and regional cortical brain volumes on structural imaging and reduced temporo-parietal cortical uptake of [^{18}F]fluorodeoxyglucose ([^{18}F]FDG) on PET and neurofilament light in the CSF and blood.

This Series paper shows how these conceptual and technical advances are implemented in the clinical practice of memory clinics in some forerunning countries, and how their experience might be a template for others. This Series[2,14] will adopt the nomenclature proposed by Petersen and colleagues (panel).[15] We will preferentially refer to cognitive impairment and cognitive disorders, and confine use of the term dementia to specifically referring to cognitive impairment associated with impairment in daily activities or when it is part of the current accepted taxonomy (eg, dementia with Lewy bodies). Issues related to the treatment of cognitive and behavioural disturbances in people with Alzheimer's disease are addressed in the second paper of this Series.[14] Controversies related to the very construct of Alzheimer's as a disease and the expected future developments in the field are the subject of the third Series paper.[2]

University of Utah, School of Medicine, Salt Lake City, UT, USA (Prof S Minoshima MD); **National Center of Neurology and Psychiatry, Tokyo, Japan** (Prof S Minoshima); **Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden** (R Ossenkoppele PhD); **Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands** (R Ossenkoppele); **Amsterdam Neuroscience-Neurodegeneration, Amsterdam, Netherlands** (R Ossenkoppele); **Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden** (Prof H Zetterberg MD); **Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden** (Prof H Zetterberg); **Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK** (Prof H Zetterberg); **UK Dementia Research Institute at UCL, London, UK** (Prof H Zetterberg); **Hong Kong Center for Neurodegenerative Diseases, InnoHK, Hong Kong, China** (Prof H Zetterberg); **Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA** (Prof H Zetterberg); **Centre for Brain Research, Indian Institute of Science, Bangalore, India** (Prof H Zetterberg); **Department of Neurology, Mayo Clinic, Rochester, MN, USA** (Prof R C Petersen MD); **Institut de la Mémoire et de la Maladie d'Alzheimer, IM2A, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France** (Prof B Dubois MD); **Institut du Cerveau et de la Moelle Épinière, UMR-S975, INSERM, Hôpital de la Pitié-Salpêtrière, Paris, France** (Prof B Dubois)

*Contributed to this manuscript from the inception of the Series in May, 2024, until November, 2024 when the first version was ready to submit. Once he was employed by Eli Lilly

on November 26, 2024, he had no access to any subsequent manuscript versions or revisions and did not contribute to the project any further

Correspondence to: Prof Giovanni B Frisoni, Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva, 1205 Geneva, Switzerland
giovanni.frisoni@unige.ch

Epidemiology in clinical settings

Incidence and prevalence of Alzheimer's disease

Epidemiological studies estimated the incidence of clinically defined Alzheimer's disease dementia (without biomarkers) in Europe to be 3·4 new cases per 1000 person-years at age 65–74 years, with a consistent tripling or quadrupling of incidence every 10 years up to 36 new cases per 1000 person-years at 85 years or older.[16]

The prevalence of all-cause dementia (of which 60–70% is Alzheimer's disease or mixed Alzheimer's disease with other pathologies) was estimated at over 57 million people globally in 2021, with the prevalence set to approximately triple by 2050 due to trends in population ageing, growth, and expected trends in risk factors.[17] Estimates from 2023 set the global number of individuals with biomarker-positive Alzheimer's disease dementia at 32 million, with more than double this number with mild cognitive impairment (MCI) due to Alzheimer's disease pathology (69 million), suggesting that the global prevalence of individuals with cognitive impairment due to Alzheimer's disease is approximately 101 million.[18] Importantly for future prevention studies, the estimated number of cognitively unimpaired individuals with abnormal Alzheimer's disease biomarkers is approximately three times larger than MCI and Alzheimer's disease-dementia cases together (315 million).[18] Future integration of blood biomarkers in population-based studies of the incidence and prevalence of Alzheimer's disease will improve the accuracy of estimates[19] and allow better estimates of incidence and prevalence of mixed forms of dementia (eg, neurodegenerative and vascular), which are increasingly frequent with older age.[20]

Although most studies found that women have a higher prevalence of dementia than men, in part due to longer survival, the weight of biological (sex) and cultural (gender) factors is unclear.[21,22] Stark racial and ethnic disparities have been consistently found in both the prevalence and incidence of dementias, although most evidence comes from the USA, with few additional studies from countries including the UK, Singapore, and China.[23–28] The incidence of all-cause dementia is about 27 cases per 1000 person-years for African Americans aged 64 years and older, compared with about 19 cases per 1000 person-years for White Americans, and about 15 cases per 1000 person-years for Asian Americans.[23] Many of the racial and ethnic disparities in dementia risk can be accounted for by cardiovascular disease risk and social determinants of health: the conditions of the environments where people are born, live, work, and age.[29,30] About 30% of patients with dementia are institutionalised.[31]

Although the overall number of individuals with all-cause dementia is expected to increase, repeated observations have suggested that the age-specific incidence of all-cause dementia in higher-income countries might be decreasing.[32] This decline might be attributable to population-level increases in educational attainment, better control of cardiovascular and metabolic risk factors, and improved socioeconomic conditions.[33–35] These observations indicate that prevention of dementia, including Alzheimer's disease dementia, is not only possible but is currently taking place in high-income countries; similar changes should be promoted in low-income and middle-income countries, where the greatest increment of prevalence is expected in the coming decades.[36] However, more recent modelling of data from the UK has raised concerns about a potential reversal of these positive trends due to an increasing prevalence of unhealthy behaviours such as obesity, sedentary lifestyle, and type 2 diabetes.[37] Decision-makers should be aware that brain health for the community is a fragile state, and positive trends can quickly reverse if not consolidated with appropriate health-care policies and interventions.

For clinic-based studies, the accuracy of the detection of Alzheimer's disease is highly dependent on the diagnostic criteria framework. The use in the same clinical population of the four biomarker-based diagnostic criteria, developed between 2011 and 2021, resulted in 43% of individuals receiving discordant diagnoses, largely due to differences in the weighting of amyloid and tau biomarkers and clinical symptoms.[38] Comparative studies of the two most recent and popular diagnostic criteria are not yet available.[39,40]

Although biomarker-based criteria have the potential to allow a very early diagnosis of Alzheimer's disease in the clinic (biomarkers of Alzheimer's disease pathology are positive long before the development of cognitive symptoms), in practice, diagnosis is often delayed due to structural factors.[41–44] Many patients experience a prolonged interval between symptom onset and formal diagnosis, estimated at around 20–50 months.[41–44] Implementation of blood-based biomarkers together with cognitive screening tests in the primary care system has the potential to help to reduce those delays in some health-care systems.[45]

Risk and protective factors: lifestyle, genetic, and biological

Clinicians can use risk factors to categorise patients into risk strata for targeted secondary prevention interventions. Older age is the strongest risk factor for sporadic Alzheimer's disease,[1] but genetic and non-genetic risk factors also play a role. *The Lancet* Commission identified 14 modifiable factors[46] that might account for 45% of all dementia cases in the general population: lower level of education, hearing loss, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation, untreated vision loss, and high LDL cholesterol. Other possible risk factors include sleep disturbances and herpes infection.[47–49]

Increases in risk for individuals are modest for most risk factors: risk ratios (RR) range from 1·1 to 2·2,

amounting to 10% to 120% greater risk than the risk-free population.[46] However, the cumulative risk of an individual can be sizable when they carry multiple risk factors.

The *APOE* ε4 allele is the strongest genetic risk factor for non-monogenic Alzheimer's disease: when compared with ε3 carriers, the RR is between 2·5 and 3 for non-Hispanic White ε4 heterozygotes, and between 7 and 10 for ε4 homozygotes, who have a lifetime risk of 40–60%, which is in the range of BRCA1 mutations for breast cancer.[46,50,51] Imaging and fluid biomarkers of brain β-amyloid and tau pathology, and neurodegeneration in cognitively unimpaired individuals, are also associated with risk for dementia and incident cognitive decline.[52,53] Secondary prevention of Alzheimer's disease in cognitively unimpaired individuals at high risk,[54] addressed in the third paper of this Series,[2] leverages on an accurate evaluation of all the above risk factors (for an extended version of this section, see appendix p 12).

Trajectories of normal cognitive ageing and Alzheimer's disease

The earliest event detectable by available biomarkers in Alzheimer's disease is the extracellular deposition of aggregated β-amyloid peptides in plaques (amyloid: A), followed by the intraneuronal deposition of hyperphosphorylated tau in neurofibrillary tangles and neuropil threads (tau: T), synaptic dysfunction and neuronal death (neurodegeneration: N), and, finally, progressive cognitive impairment.[55–57] More details on the neurobiological mechanisms linking the amyloid cascade to clinical dysfunction can be found elsewhere.[58,59]

The A-T-N model is being revised and updated to accommodate the heterogeneity of observed trajectories.[58,60,61] At least three relatively distinct clusters of cognitive trajectories have been identified that differ in frequency, age of onset of pathology, topography of tau pathology and neurodegeneration, clinical phenotype (memory-predominant *vs* non-amnestic), and speed of cognitive decline (figure 1): (1) carriers of autosomal dominant Alzheimer's disease mutations; (2) Alzheimer's disease biomarker positive carriers of the *APOE* ε4 allele; and (3) Alzheimer's disease biomarkers-positive individuals who are not carriers of the APOE ε4 allele. Heterogeneity in the timing and rate of β-amyloid accumulation and the development of cognitive impairment occurring downstream in the amyloid cascade are modulated by stochastic factors such as non-*APOE* genes, non-Alzheimer's disease pathologies, age, sex, lifestyle factors, frailty, and environmental exposures such as literacy, educational attainment, and early life cognitive engagement.[58,60,62–65] Stochastic factors modulate resistance to the development of β-amyloid pathology, or in the presence of β-amyloid pathology, resilience against cognitive decline.[66]

The trajectories shown in figure 1 are critically different from the so-called Jack's curves,[67] for at least two reasons: (1) Jack's curves take a disease-centric approach and represent biomarker trajectories, whereas figure 1 takes a patient-centred approach and represents cognitive trajectories;[2] (2) unlike Jack's curves, figure 1 shows the trajectories of people who never develop biomarker changes and of those who, despite being biomarker positive, never develop cognitive impairment or dementia. This is a key concept when discussing the risk of cognitive impairment and dementia in cognitively unimpaired individuals with risk factors.[2]

Cognitive screening in the general medical practice

Patients presenting to memory clinics differ on average from individuals with cognitive impairment in the general population in that they are typically younger, come from higher socioeconomic backgrounds, are less diverse, have fewer comorbidities, exhibit less severe cognitive impairment, have higher education, and benefit from social and family support that enables access to specialised care.[68]

See Online for appendix

In primary care settings, untargeted cognitive screening is not generally recommended.[69,70] However, targeted cognitive examination in individuals with cognitive complaints is recommended as it improves the diagnosis and care of cognitive disorders.[71,72] The involvement of primary care physicians in the clinical journey of cognitive patients is highly variable among countries.[73] In European countries, before anti-amyloid antibodies were approved, a strong association was found between the authorisation to prescribe traditional dementia drugs (cholinesterase inhibitors and memantine) and pursuing dementia diagnostic work-up in primary care.[73] The availability of



Figure 1: **Cognitive trajectories during ageing by genetic and biomarker status**
Trajectories are those implied by the pathophysiological probabilistic amyloid cascade model of Alzheimer's disease[58] and are consistent with current diagnostic frameworks for Alzheimer's disease.[39,40] Arrows denote cognitive trajectories of autosomal dominant Alzheimer's disease mutation carriers (red), *APOE* ε4 allele carriers (purple), and non-carriers (green). Dark and light colours denote those who enter (on amyloid cascade) and do not enter the amyloid cascade (off). Arrow thickness is roughly proportional to the population prevalence. Red, purple, and green shading around some arrows denote variability within trajectories due to stochastic factors (non-*APOE* genes, non-Alzheimer's disease pathologies, lifestyle factors, frailty, and environmental exposures such as literacy, educational attainment, and early life cognitive engagement). More details in appendix (p 2).

anti-amyloid antibodies might further encourage primary care physicians to direct patients with memory complaints to specialist advice.

In any setting, cognitive examination should always start with history taking, which is a cornerstone in the assessment of people with cognitive complaints.[72,74,75] In Alzheimer's disease, cognitive, behavioural, and functional symptoms develop gradually in a typical pattern. Diagnosis involves gathering detailed history from patients and informants, noting symptom onset, type, and progression, and functional effect. Consideration of comorbidities, medications, laboratory tests, mood, life events, and lifestyle is essential. Self-assessment tools can help to streamline the evaluation process,[76,77] and deviations from the typical course might indicate atypical presentation or other conditions.

History taking should be complemented with a structured cognitive test to assess mental status.[72,74] General practitioners can use a short test such as the Five-Minute Cognitive Test, a combination of the clock-drawing test and a three-item word memory test;[78] the General Practitioner Assessment of Cognition taking 5 min to 10 min;[79] or the more time-consuming (10–15 min) but also more widely used Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA), which is more sensitive to mild cognitive changes.[80,81] When compared with unaided general practitioners' clinical impression alone, short cognitive testing with MoCA almost doubles the number of patients recognised as affected by dementia.[82] The Rowland Universal Dementia Assessment Scale relies less on language and school abilities than MMSE or



Figure 2: **The patient journey and diagnostic workflow for the biomarker-based diagnosis of Alzheimer's disease and other cognitive disorders in memory clinics**
The workflow is largely the result of a European inter-societal Delphi exercise.[86] Assessment follows three functional waves. Wave 1 is the first memory clinic consultation and allows to provisionally categorise patients into cognitively unimpaired and impaired, perform staging in the latter, identify the most obvious secondary causes, and prescribe diagnostic tests and exams including a cognitive battery. Wave 2 allows the exclusion of less obvious secondary causes, final cognitive staging due to the cognitive battery results, and make a syndromic diagnosis and put forward an aetiological (molecular) hypothesis. Some of the aetiological hypotheses (a, b, c, and d) are confirmed or infirmed in Wave 3 through first-line and second-line imaging and liquid biomarkers. The biomarker-based diagnosis of neurodegenerative conditions can be molecular (only for Alzheimer's disease) or topographical (all others). First-line and second-line biomarkers were selected by 22 experts from 11 European scientific societies with a Delphi procedure.[86] Innovative biomarkers are addressed in the third paper of this Series.[2] More details in appendix (p 4). AD=Alzheimer's disease. CT=computed tomography. CSF=cerebrospinal fluid. DaT=dopamine transporter. EEG=electroencephalogram. FDG=fluorodeoxyglucose. FTLD=frontotemporal lobar degeneration. LATE=limbic-predominant age-related TDP-43 encephalopathy. LBD=Lewy body disease. MIBG=metaiodobenzylguanidine. NeT=norepinephrine transporter. REM=rapid eye movement. SPECT=single-photon emission computed tomography.

MoCA and is commonly used for case identification in culturally and linguistically diverse communities in low-income and middle-income countries.[83] Currently, several digital cognitive tests are being developed and, in the future, could enable broader cognitive testing in primary care and beyond.[84]

Cognitive disorders can be heralded by non-cognitive behavioural symptoms such as apathy, affective symptoms (depression, anxiety), impulse dyscontrol (irritability, agitation), social inappropriateness, disturbances of sleep and vigilance, and psychotic symptoms (delusions, hallucinations),[85] and, especially in the oldest old, non-cognitive motor symptoms such as decreased gait speed and grip strength.[85] Cognitive screening should always be done in these cases,[70] because early stages of Alzheimer's disease pathology can underlie behavioural and motor symptoms even before cognitive impairment overcomes the threshold of complaints.

The patient journey in memory clinics

Although the patient journey might vary across memory clinics, three main functional waves of assessment take place in most memory clinics in high-income countries (figure 2). Depending on local practices and regulations, these assessments can take place over multiple visits and an extended time period or consolidated into fewer visits within a shorter time period.[87,88]

Wave 1

The first step of the journey for patients with cognitive complaints in a memory clinic consists of identifying cognitive impairment through history taking and cognitive screening (figure 2), which is key to interpreting the results of diagnostic biomarkers and for eligibility to pharmacologic treatment.[14,89]

Screening of cognitive impairment

When not done in general practice, cognitive screening takes place early on in the memory clinic with the tests described earlier. In the memory clinics of some of the coauthors of this paper, between 10% and 37% of individuals presenting with cognitive complaints are shown to be cognitively unimpaired based on cognitive testing, with a weighted mean of 13% (figure 3; appendix pp 10–11). These patients are labelled as subjective cognitive decline if they experience and report worsening of cognitive capacities or worried well, if there is a concern of developing impairment in the future, but no complaint at present.[54,90]

Clinicians should be able to recognise whether psychological or psychiatric and medical or neurological conditions underlie their complaints and concerns (eg, sleep problems, longstanding anxiety or depression, personality disorders, physical comorbidity or polypharmacy, or previous stroke), and refer them to the appropriate specialist, if indicated. When none of the above is true, patients with subjective cognitive decline or worried well can be directed to a secondary prevention patient journey, currently under development[54] and addressed in the last paper of this Series.[2]

Wave 2

In patients with cognitive impairment, delirium and non-neurodegenerative causes should be excluded before a neurodegenerative cause can be suspected and a syndromic diagnosis can be made, which will give rise to an aetiological neurodegenerative hypothesis. The pertinent information is collected through functional and behavioural assessment, physical and neurological examination, a cognitive battery, blood routine, and MRI or CT of the brain (figure 2).

Excluding delirium and non-neurodegenerative causes of cognitive impairment

A rapidly progressing cognitive impairment (eg, within days or weeks) indicates delirium (formerly known as acute confusional state; panel). The delirium can be due to non-neurological (eg, electrolyte imbalance, infections, toxic substances, metabolic decompensation, heart failure, or alcoholic encephalopathy) or neurological causes (eg, encephalitis, Creutzfeldt-Jakob disease, cerebral vasculitis, or cerebral amyloid angiopathy-related inflammation), with all conditions requiring urgent evaluation (figure 2).[91,92] Of note, delirium does not rule out an underlying chronic progressive cognitive disorder (so-called delirium superimposed on dementia).[93] Indeed,



Figure 3: **Taxonomy of patients and use of diagnostic biomarkers at selected memory clinics**
For each colour, cases diagnosed with (dotted) and without (non-dotted) cerebrospinal fluid or PET biomarkers are shown. Based on a survey of 16 526 new consecutive diagnostic patients consulted from Jan 1, 2022, to Dec 31, 2023, in the memory clinics of Amsterdam, Cologne, Copenhagen, Geneva, Lund, Munich, and Paris. Reversible conditions include normal pressure hydrocephalus, meningioma, metabolic conditions, depression. Other section includes low achievement, psychiatric conditions, unsuccessful brain ageing. No cognitive impairment includes subjective cognitive decline, functional cognitive and other psychiatric disorders, neurologic diseases, physical comorbidity, somatic comorbidity, polypharmacy. More details in appendix (pp 10–11).

chronic progressive cognitive disorders increase the risk of delirium (three-fold to four-fold) due to non-neurological causes[94] and 30% of individuals with de-novo delirium develop overt cognitive impairment within 5 years,[95] especially in frail patients.[96] Delirium is twice as frequent in frail patients,[96] who tend to be older than robust patients[65] and feature an increased risk of adverse outcomes. Although no data are available at the moment, it is reasonable to assume that frail patients might not be the prime candidates for treatment with anti-amyloid monoclonal antibodies (addressed in the second paper of this Series).[14] The concept of frailty, its meaning as an indicator of biological as opposed to chronological age, its assessment, and its relevance to cognitive impairment have been reviewed elsewhere.[65] If delirium is identified, the cognitive disorder diagnostic pathway proposed here should be stopped and, if deemed necessary, it can be started again after the delirium episode has resolved.

Information on function in activities of daily living should be assessed by questioning caregivers[97,98] and can be staged into minimal, mild, moderate, and severe disability with the help of structured rating scales.[99] Behavioural and psychological symptoms (agitation, aggression, insomnia, depression, anxiety, hallucinations, and delusions) are generally assessed through an unstructured collection of historical information.[14,70] Staging behavioural and psychological symptoms into minimal, mild, moderate, and severe is also recommended[15] as severity drives treatment. The assessment and treatment of behavioural and psychological symptoms are addressed in the second paper of this Series.[14]

An important question is whether a non-rapidly progressive, non-confusional cognitive impairment is due to potentially curable causes mimicking a neurodegenerative disease, whereby patients could improve with appropriate interventions, such as weaning cognitively impairing medications or treating underlying conditions such as hypothyroidism, depression, or sleep apnoea.[100] These conditions are often detected and managed by primary care providers, but memory clinics should rule out these conditions in the earliest stages of the patient journey (figure 2). Secondary causes of cognitive impairment that should never be disregarded include neurodevelopmental disorders, medical comorbidities, and conditions affecting the white matter. The triad consisting of gait disturbances, urinary incontinence, and non-amnestic cognitive impairment can point to idiopathic normal pressure hydrocephalus or small vessel cerebrovascular disease.[101] MRI of the brain is key to the differential diagnosis, as it can identify lacunes, micro-haemorrhages, superficial siderosis, enlarged perivascular spaces, and extensive white matter changes due to small-vessel disease or cerebral amyloid angiopathy.[102] MRI is also sensitive to detect secondary causes of cognitive impairment, such as subdural haematoma, brain tumours, or idiopathic normal pressure hydrocephalus (figure 2).[86]

Syndromic diagnosis and aetiological hypothesis

In patients with slowly progressive cognitive impairment not due to the conditions mentioned earlier, a neurodegenerative disease should be suspected. Diagnostic reasoning involves defining the clinical syndromic presentation and, if indicated and possible, identifying the underlying molecular pathophysiology.[15] Syndromes are made of cognitive, behavioural or psychiatric, and motor and neurological symptoms, and atrophy patterns (figure 2). The same clinical–radiological syndrome can be due to different pathologies—eg, β-amyloid and tau, α-synuclein, or transactive response DNA binding protein (TDP)-43. However, in general, pathologies are more frequent in some syndromic diagnoses than others, such that syndromic diagnoses drive an aetiological hypothesis of molecular pathology (figure 2).

Cognitive test batteries are combinations of selected neuropsychological tests aimed at clarifying the existence of impairment when screening results are inconclusive and outlining a profile of cognitive impairment. The tests evaluate functions across various cognitive domains—memory, executive function, attention, language, praxis, gnosis, and social cognition—by contrasting individual patient results to age-specific and education-specific population norms.[103] There is no general standard for the definition of impairment, but an outcome of 1·5 standard deviations below the adjusted means for age, sex, and education on normally distributed cognitive test scores, corresponding to about the 95th percentile, is often used in addition to clinical judgment as a threshold between normal and impaired. Below normal cognitive test results, when combined with a history of progressive cognitive decline reported by the patient or, if available, by a reliable informant, are used to infer progressive cognitive decline. Cognitive batteries also enable assessment of the severity of cognitive impairment and can be used to monitor changes over time.

The profile of cognitive impairment across cognitive domains is a major contributor to a syndromic diagnosis. In more than 80% of cases fulfilling the neuropathological diagnosis for Alzheimer's disease, the typical phenotype consists of an amnestic syndrome of hippocampal type, characterised by a low free recall that is not normalised by cueing.[104] This memory profile differs from that observed in most non-Alzheimer's dementias and correlates with Alzheimer's disease pathology.[105] Atypical cognitive presentations of Alzheimer's disease pathology are less frequent and include visuoperceptive, language, frontal, visuospatial, or apraxic changes.

Cognitive profiles are more closely linked to the regional distribution of synaptic dysfunction and neuronal loss (ie, neurodegeneration) than to the specific molecular pathology underlying a neurodegenerative disease. Although certain clinical phenotypes and neurodegeneration topographies are statistically associated with particular molecular pathologies—such as the preferential involvement of the inferior frontal and insular regions in

frontotemporal lobar degeneration with tau pathology (FTLD-tau), the anterior temporal lobe in FTLD-TDP type C, and temporo-parietal atrophy in Alzheimer's disease within the language network—these associations are too weak to be clinically actionable (eg, only ~75% of logopenic variant primary progressive aphasia are underpinned by Alzheimer's disease pathology).[106] Algorithms trying to identify the underlying proteinopathy from a given clinical–radiological syndrome have so far shown poor performance.[107]

Neurodegeneration in Alzheimer's disease is a relatively late event and can be appreciated with specific sequences on structural MRI.[88] Brain CT is less sensitive but can replace MRI when it is not available or contraindicated.[108] Brain atrophy associated with Alzheimer's disease can be differentiated from ageing-associated atrophy as it is more severe and comes in topographic patterns matching cognitive profiles.[109]

Wave 3

In an increasing number of memory clinics, the aetiological hypothesis is confirmed or refuted through biomarker assessment (figure 4). Only biomarkers of β-amyloid, tau, and α-synuclein pathology (in the blood, CSF, and on PET) allow an aetiological diagnosis. Other biomarkers currently in use in memory clinics are biomarkers of neurodegeneration (biomarkers of glucose metabolism on PET, brain dopaminergic denervation on single-photon emission computed tomography, and cardiac noradrenergic denervation on scintigraphy),[86] which allow the presence and topography of synaptic and neuronal loss to be defined more clearly and accurately than atrophy assessment on structural MRI alone or the exploration of specific neurotransmission pathways affected by the degenerative process. Although non-aetiological, this topography-based diagnosis can be used as a proxy, albeit an imperfect one, of the aetiological hypothesis.[111]

We provide here an overview of fluid and imaging biomarkers of β-amyloid pathology, tau pathology, and neurodegeneration that are useful in the clinic and that have been, or will soon be, approved for clinical use by regulatory authorities in the USA and Europe. Research-use-only tests are addressed in the third paper of this



Figure 4: **Typical biomarker profiles across pure pathology neurodegenerative cognitive disorders.**
Blue colour in glucose PET renderings denotes substantial hypometabolism. Orange/red/purple/white colours in nigrostriatal SPECT imaging and amyloid and tau PET denote increased tracer uptake. Images come from the archive of one of the co-authors (VG). More details in appendix (p 8). AD=Alzheimer's disease with typical amnestic phenotype. CSF=cerebrospinal fluid. DLB=dementia with Lewy bodies. FTLD=frontotemporal lobar degeneration with behavioural phenotype. LATE=limbic-predominant age-related TDP-43 encephalopathy.[110] PDD=Parkinson's disease dementia. SAA=seed amplification assay. SPECT=single-photon emission computed tomography.

Series.[2] The ultimate aetiological diagnosis is done through neuropathological assessment, which is not discussed here and can be found addressed in other reviews.[114]

Importantly, PET imaging and fluid markers are not interchangeable. PET reveals the burden of insoluble Alzheimer's disease-related protein aggregates, whereas fluid biomarkers reflect dysmetabolism (altered production or clearance) in soluble biomarkers that are in dynamic equilibrium with insoluble aggregates. The balance of production and clearance of β-amyloid and tau proteins in body fluids (CSF and blood) indirectly reflects the presence of Alzheimer's disease neuropathology. The distribution of insoluble β-amyloid plaques and neurofibrillary tangles can be visualised and quantified via PET imaging, but only once the pathological load reaches concentrations defined as moderate on pathology.[10,39] Notably, fluid biomarkers are more sensitive to the earliest changes in the pathological metabolic pathway than clinical amyloid PET scans, which show a clear signal at the individual level only when pathology burden becomes moderate.[115–117] In contrast to fluid biomarkers, PET informs on both the presence and the topography of pathology, which, in the case of tau PET, correlates with the clinical phenotype.[118]

Biomarkers of β-amyloid pathology

Clinically approved amyloid PET tracers are blood–brain barrier permeable small molecules marked with [^{18}F] (florbetapir, florbetaben, and flutemetamol) that bind with high affinity to β-amyloid plaques and can be detected and mapped by appropriate PET hardware and software. The interpretation of amyloid PET images for clinical purposes is based on standardised visual assessment by physicians who have received formal accreditation.[119] Amyloid accumulation can also be quantified by calculating the relative uptake of the tracer in cortical areas in comparison to a reference region not affected by pathology, most commonly the cerebellum. To allow standardisation across different amyloid PET tracers, a common scale (centiloid) has been proposed, where the values of 0 and 100 represent the anchor points corresponding to a typically normal and a typically pathological PET scan.[120] Positivity to amyloid PET, with appropriate thresholds, allows identifying with high sensitivity and specificity intermediate to high Alzheimer's disease neuropathological changes, associated with intermediate tau pathology (Braak stage ≥III [glossary of terms]).[121]

In the CSF, the accumulation of β-amyloid plaques in the brain parenchyma is preceded by a reduction of soluble Aβ42 peptide relative to the more abundant Aβ40 peptide, resulting in a low Aβ42:Aβ40 ratio.[122–125] The ratios of Aβ42:Aβ40, p-tau181:Aβ42, and total tau:Aβ42 are more strongly associated with β-amyloid pathology than CSF Aβ42 alone,[11–13] and current CSF tests approved by the US Food and Drug Administration (FDA) for Alzheimer's disease use these ratios rather than CSF Aβ42 alone to establish the presence of β-amyloid plaques.[89] When both β-amyloid and tau fluid biomarkers are abnormal, specificity to Alzheimer's disease neuropathology is impeccable, albeit at the expense of decreased sensitivity.[126]

Clinically approved PET imaging and CSF tests for β-amyloid pathology show agreement on the classification of amyloid status in about 90% of individuals.[11,89] Disagreements can occur with a positive CSF test and negative amyloid PET scan, particularly in patients with low amounts of β-amyloid pathology.[127,128] Evidence from large-scale prospective trials shows that both techniques have a relevant effect on diagnostic thinking and clinical management of patients.[129–131] As is the case with many diagnostic tests in clinical medicine,[132] few studies have examined the effects of biomarker testing on patient-related outcomes, with conflicting findings.[133,134]

Biomarkers of tau pathology

At least eight different pathologic variants of misfolded tau have been identified, some of which are associated with relatively specific topography and clinical phenotype such as those of progressive supranuclear palsy and corticobasal degeneration.[135] Similarly to β-amyloid, the tau pathology observed in Alzheimer's disease (3R-4R; panel) can be assessed through PET imaging and CSF measures, and more recently plasma measurements. Tau-PET becomes abnormal when insoluble 3R-4R tau aggregates have already spread into the neocortex.[136,137] Although the topography of β-amyloid deposition is only poorly correlated to the clinical phenotype, the topography of tau evaluated through PET is closely related to cognitive profile[138] and clinical stage.[53,139–142] The visual interpretation protocol, currently approved for clinical use (validated against autopsy), requires a binary interpretation that is restricted to the detection of advanced neocortical tau pathology, corresponding to Braak stages V and VI.[143] Flortaucipir, a first-generation tracer specific to 3R-4R tau aggregates but not to other tauopathies such as progressive supranuclear palsy and corticobasal degeneration, is currently approved for clinical use only in the USA and the EU. However, few centres in the USA and Europe do clinical tau PET scans.

In the CSF and blood, decreased Aβ42/Aβ40 is accompanied by increases in tau species, including phosphorylated tau at positions 181 (p-tau181) and 217 (p-tau217).[122–125] In larger studies, the ratio of phosphorylated to non-phosphorylated p-tau217 (pT217/T217) is a slightly better biomarker of amyloid and tau pathology than the absolute concentration of p-tau217.[124,144] Some medical comorbidities, such as chronic kidney disease, can affect amounts of blood biomarkers including p-tau217 concentrations,[145] and biomarker ratios such as pT217/T217 might mitigate these effects.[146,147] Importantly, p-tau217 and pT217/T217 in the CSF and blood increase early in the natural history of Alzheimer's disease pathology and continue to increase as amyloid and tau pathology accumulate, unlike Aβ42/Aβ40, which decreases early but then plateaus and has lower

associations with tau pathology.[124,148–151] Blood tests for amyloid pathology are clinically available in the USA and a few other countries, including plasma p-tau217 measures with high positive and negative predictive values; these tests can be used early on in the diagnostic journey and can reduce the need for CSF biomarkers and PET scans by approximately 80–90%.[4,149,152–155] The first FDA-cleared blood-based in-vitro diagnostic device for the detection of Alzheimer's disease pathology in patients with symptoms is a ratio of p-tau217 to Aβ42 measured with Lumipulse technology.[155]

Biomarkers of neurodegeneration

Neurodegeneration markers provide the patho-physiological link between the molecular pathology and the clinical phenotype. Synaptic density is the best pathological correlate of the clinical phenotype.[156,157] It is a working assumption in the field that no degree of cognitive impairment can be attributed to Alzheimer's disease—or any other neurodegenerative condition—without some degree of neurodegenerative changes, whether measurable or not. Neurodegeneration markers can support the differential diagnosis between neuro-degenerative and non-neurodegenerative conditions. Additionally, the topography of neurodegeneration on MRI contributes to the clinicoradiological syndromic characterisation of patients early in the diagnostic journey (figure 4). Medial temporal atrophy is present in 75–85% of patients with Alzheimer's disease in the mild to moderate cognitive stages, which can be easily appreciated on T1-weighted coronal scans[109] and rated with a simple visual rating scale.[158,159] Additionally, 82% of patients with a behavioural frontotemporal syndromic profile have severe, often asymmetric, anterior frontal or temporal atrophy, or both, on MRI.[109] Severe amygdalar atrophy is typical of limbic-predominant age-related TDP-43 encephalopathy and requires additional specific rating on T1-weighted axial scans.[160]

In the natural history of Alzheimer's disease, atrophy on MRI is a relatively late phenomenon and is often difficult to differentiate from normal ageing or is hardly detectable (Alzheimer's disease with minimal atrophy).[161] Glucose hypometabolism on [^{18}F]FDG-PET is more sensitive to the neurodegenerative process than atrophy on MRI.[162] The detection of grey matter hypometabolism can corroborate the presence of a neurodegenerative disease in uncertain cases, and the topographic pattern of hypometabolism can help to differentiate Alzheimer's disease from non-Alzheimer's disease conditions where molecular biomarkers are not available (eg, frontotemporal lobar degenerations and dementia with Lewy bodies). Excellent reviews on the clinical and biomarker features of non-Alzheimer's disease neurodegenerative conditions are available elsewhere.[163–167]

CSF and plasma neurofilament light are the best-established clinically available fluid biomarkers of neurodegeneration, with increased amounts across neurodegenerative diseases and particularly high amounts in frontotemporal dementia, amyotrophic lateral sclerosis, vascular dementia, and rapidly progressive Alzheimer's disease.[168] In the USA, plasma neurofilament light can be ordered and might have some diagnostic utility, especially in combination with plasma p-tau217, for patients in whom clinicians are considering frontotemporal dementia (higher neurofilament light, lower p-tau217) versus either Alzheimer's disease (lower neurofilament light, higher p-tau217) or dementia with Lewy Bodies (lower neurofilament light, lower p-tau217).[169,170]

Biomarker use in the clinic

Although the biomarker profiles of the most frequent neurodegenerative conditions seen in memory clinics are markedly different when multiple biomarkers are considered (figure 4), reimbursement and logistical considerations typically restrict providers to ordering one biomarker at a time. Appropriate use criteria for amyloid and tau PET have been proposed and recently updated.[171] A Delphi panel of European delegates from pertinent scientific societies has identified first-line and second-line biomarkers with the greatest chance of supporting specific aetiological hypotheses (figure 4). The panellists did not take accessibility and reimbursement into account, which vary across Europe and can profoundly affect the choice of which biomarker to investigate—eg, PET versus CSF testing when the aetiological hypothesis is Alzheimer's disease (figure 2). Similar appropriate use recommendations have been provided for the use of CSF biomarkers.[172] Recommendations for blood biomarkers have also been published,[173] but are currently being updated given advancements in Alzheimer's disease blood tests.

A few notes of caution should be emphasised regarding the interpretation of diagnostic biomarkers in clinical settings. First, particularly in the oldest-old patients, multiple pathologies co-occurring with Alzheimer's disease are the rule rather than the exception,[174] and clinical syndromes and biomarker profiles are sometimes less clear-cut than described earlier. In these cases, it can be difficult to ascertain whether, and to what extent, Alzheimer's disease and non-Alzheimer's disease components contribute to the observed cognitive impairment. This distinction can be relevant in clinical settings where anti-amyloid monoclonal antibodies are available, and an accurate estimate of the contribution of the amyloid cascade to the cognitive phenotype can help to predict the therapeutic success and inform treatment decisions. Importantly, when Alzheimer's disease biomarkers are negative, it is unlikely that Alzheimer's disease pathology underlies the clinical phenotype. Given the increasing frequency of copathology with advancing age, the Delphi panellists contributing to the diagnostic workflow in figure 2 strongly recommended the use of diagnostic biomarkers for individuals younger than 70 years, recommended to consider them based on

individual clinical characteristics in those aged 70–85 years, and did not recommend them in individuals older than 85 years.[86] However, a negative biomarker result is in general a strong argument against a diagnosis of Alzheimer's disease, and particularly in older individuals when Alzheimer's disease pathology is highly prevalent.[175] In general, clinicians should consider repeating biomarker testing if results are discordant with clinical suspicion.

Second, before amyloid targeting therapies were available—and still today in countries where such treatments are unavailable—the value of a biomarker-based diagnosis (whether molecular or topographic) lay in its ability to reduce misdiagnoses, which, in turn, helps to prevent the inappropriate use of cholinesterase inhibitors and memantine in patients with frontotemporal degenerations,[176] and of neuroleptics in patients with dementia with Lewy bodies.[177,178] Moreover, a substantial proportion of patients with MCI or mild dementia assign an inherent value to receiving an accurate diagnosis.[179,180] In the era of amyloid-targeting therapy, however, a biomarker-based diagnosis has become indispensable for identifying patients who might be candidates for anti-amyloid monoclonal antibody treatment—estimated to be between 5% and 17% of memory clinic patients with MCI or mild dementia.[181,182]

Multiple Alzheimer's disease blood tests are clinically available as laboratory-developed tests in the USA and other countries, and must meet technical standards to ensure consistent measurement of the biomarker of interest.[183] So far, only one of the Alzheimer's disease blood tests (Lumipulse p-tau217:Ab42 ratio) has received full FDA clearance. Blood biomarkers of Alzheimer's disease pathology hold promise for improved diagnosis,[184,185] particularly in primary care settings and in low-income and middle-income countries, where cognitive disorders are currently under-recognised, underdisclosed, undertreated, and undermanaged.[186–188]

Most PET, CSF, and blood tests validation studies have been done in primarily non-Hispanic White populations. Racial and ethnic differences in amyloid PET, CSF biomarkers, and blood biomarkers have been reported by some studies but not others.[189–191] Factors such as differential selection effects, rates of medical comorbidities, and prevalence of amyloid pathology might be associated with groups defined by race or ethnicity.[191–193] Therefore, when biomarker tests are done in patients identifying with racial or ethnic groups that have been under-represented in biomarker validation studies, clinicians should interpret the results with a higher level of uncertainty than they would for well represented patient groups, and it might be reasonable to consider a second test in patients with intermediate results.

Finally, in clinicopathological studies, the accuracy of biomarkers is 90% or higher versus moderate and severe Alzheimer's disease pathology burden.[194,195] However, there might be complexities in clinical practice that affect diagnostic accuracy, such as inter-rater variability in classifying amyloid PET status[196] and insufficient uniform measures and cut-offs for both CSF and blood tests.[172,173,197] Some discordance exists between different biomarker modalities and between biomarkers and neuropathology, particularly in individuals with low amounts of amyloid pathology and intermediate biomarker abnormality.[198,199] Given this margin of error, the degree of biomarker abnormality rather than a binary result should be reviewed if available.

Furthermore, the clinician should consider the pretest probability of abnormality for a given patient, as the positive and negative predictive values of any test are affected by the prevalence of the condition of interest in the diagnostic population.[89,200] In the memory clinic diagnostic setting, for example, the positive predictive value of blood biomarkers for Alzheimer's disease pathology will be higher in patients with more severe cognitive impairment than in those with milder cognitive impairment, and vice versa for the negative predictive value.[185] This highlights the importance of clinical phenotyping before interpreting biomarker results.

More details on the differential diagnosis of Alzheimer's disease from other conditions and the diagnostic workflow of figure 2 can be found elsewhere.[86] Importantly, biomarker testing should generally not be done in cognitively unimpaired individuals outside of clinical trials and research studies because the resulting information is currently of uncertain clinical interpretation and non-actionable.[172,173,201]

Conclusions

In this Series paper, we have shown that the theory and practice surrounding Alzheimer's disease and its diagnosis are undergoing dynamic and lively evolution. A better understanding of the natural history of biomarkers associated with Alzheimer's disease pathology has enabled the development of patho-physiologically sensible and clinically useful diagnostic criteria. The increased use of, and experience with, biomarkers in clinical settings has facilitated the development of diagnostic workflows that support earlier, more accurate, and sustainable diagnosis and differential diagnosis of Alzheimer's disease. Advances in the biomarker field have improved the accuracy and structure of diagnostic assessment in all patients, regardless of whether molecular biomarkers are used.

The availability of anti-amyloid monoclonal antibodies in some countries has further accelerated the uptake of diagnostic biomarkers, although the benefits of a timely and accurate diagnostic assessment extend well beyond the indications for monoclonal antibody treatment. Exciting technological advancements have enabled the development of easily accessible blood-based biomarkers, which have already started yet another diagnostic revolution, with radical changes in the diagnostic patient journey in high-income and hopefully soon in

low-income and middle-income countries. The state-of-the-art treatments of cognitive and non-cognitive behavioural symptoms in patients with Alzheimer's disease will be addressed in the second paper of this Series on Alzheimer's disease.[14]

Contributors

GBF drafted the structure of the paper and an early draft of text, tables, and figures. EN was the main contributor to the Epidemiology section. VG was the main contributor to the Wave 3 section and refined figure 4. SES contributed to the Wave 3 section. WMvdF, FJ, and NV contributed to the Cognitive screening in the general medical practice, Wave 1, and Wave 2 sections. All coauthors revised the manuscript at least once, contributed to the literature search, and contributed important intellectual content. Authors appearing on individual papers of the Series contributed to those papers only and had no contribution to the other papers. All authors had the opportunity to read all papers once completed and agree that the paper they co-authored appears in this Series.

Declaration of interests

GBF has received funding through the Private Foundation of Geneva University Hospitals from: Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Geneva, Switzerland; Fondation Segré, Geneva, Switzerland; Ivan Pictet, Geneva, Switzerland; Race Against Dementia Foundation, London, UK; Fondation Child Care, Geneva, Switzerland; Fondation Edmond J Safra, Geneva, Switzerland; Fondation Minkoff, Geneva, Switzerland; Fondazione Agusta, Lugano, Switzerland; McCall Macbain Foundation, Toronto, Canada; Nicole et René Keller, Geneva, Switzerland; Fondation Accompagnement, Écoute, Temps, Attention, Soutien, Geneva, Switzerland; has received funding through the University of Geneva or Geneva University Hospitals: for investigator-initiated sponsored studies from ROCHE Pharmaceuticals, OM Pharma, EISAI Pharmaceuticals, Biogen Pharmaceuticals, and Novo Nordisk; has received funding for competitive research projects from: Horizon 2020, Innovative Medicines Initiative, Innovative Medicines Initiative 2, Swiss National Science Foundation, and VELUX Foundation; has received consulting fees from: Biogen, Diadem, Roche; has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from: Biogen, Roche, Novo Nordisk, GE HealthCare. OH declares consulting fees from AC Immune, BioArctic, Biogen, Bristol Meyer Squibb, C2N Diagnostics, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, Eisai, and Siemens. OH contributed to this manuscript from the inception of the Series in May, 2024, until Nov 26, 2024, when the first version was ready to submit. Once he was employed by Eli Lilly on Nov 26, 2024, he had no access to any subsequent manuscript versions or revisions and did not contribute to the project any further. EN declares grants or contracts from National Institute on Aging (paid to her institution). VG declares grants or contracts from Siemens Healthineers and GE Healthcare (paid to her institution); received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk and Janssen. SES declares grants or contracts from Barnes-Jewish Hospital Foundation and National Institute on Aging; consulting fees from Eisai and Novo Nordisk; payment or honoraria from Eli Lilly, University of Wisconsin, St Luke's Hospital, Houston Methodist Medical Center, Weill Cornell, University of Massachusetts, Zucker School of Medicine, Medscape, Alzheimer's Therapeutic Research Institute University of Southern California, University of Washington, and University of Indiana; support for attending meetings and/or travel from National Institute on Aging, Alzheimer's Association and US Against Alzheimer's; participation on data safety monitoring boards or advisory boards from WHO, University of Washington, University of Indiana, and University of Michigan; a leadership or fiduciary role for Greater Missouri Chapter of the Alzheimer's Association, Global CEO initiative workgroup on Blood-Based Biomarkers, advisory group on Risk Evaluation Education for Dementia and Foundation for the National Institutes of Health Biomarkers Consortium; receipt of equipment, materials, drugs, medical writing, gifts, or other services from C2N Diagnostics. WMvdF has received funds from ZonMw, Nederlandse Organisatie Voor Wetenschappelijk Onderzoek (Netherlands Organization for Scientific Research), European Union Innovative Health Initiative, European Union Joint Programme Neurodegenerative Disease Research, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland (Topsector Life Sciences & Health), Dioraphte Foundation, Gieskes-Strijbis Fund, Equilibrio Foundation, Edwin Bouw Fund, Pasman Foundation, Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics for research programmes; holds the Pasman chair, all paid to her institution; is recipient of A Personalized Medicine Approach for Alzheimer's Disease, which is a public–private partnership receiving funding from ZonMW (73305095007) and Health~Holland (Topsector Life Sciences & Health) (PPP-allowance; LSHM20106); is recipient of TAP-dementia, ZonMw (10510032120003); is recipient of the Innovative Health Initiative Joint Undertaking projects PROMINENT (101112145) and AD-RIDDLE (101132933), all paid to her institution; is consultant to Oxford Health Policy Forum, Roche, Eisai, and Biogen MA, all paid to her institution; has been an invited speaker at Biogen MA, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council, all paid to her institution; participated in advisory boards of Biogen MA, Roche, and Eli Lilly and is member of the steering committee of Novo Nordisk's Evoke/Evoke+ phase 3 trials, all paid to her institution; is member of the steering committee of PAVE, and Think Brain Health; and was associate editor of Alzheimer, Research & Therapy in 2020–21 and is associate editor at *Brain*. FJ declares grants or contracts from Value based health care in memory clinics (Roche); consulting fees from Abbvie, Biogen, Eli Lilly, Eisai, Grifols, Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Eli Lilly, Eisai, GE Healthcare, Grifols, Janssen-Cliag, Roche; participation on data safety monitoring boards or advisory boards for AC Immune; a leadership or fiduciary role in European Alzheimer's Disease Consortium, Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, German Memory Clinic Network board and InRad Foundation. NV declares grants or contracts from Union Nationale pour les Intérêts de la Médecine, Fondation Claude Pompidou, Fondation Alzheimer, Fondation pour la Recherche sur l'Alzheimer, Biogen, Eli Lilly, Roche, Eisai, Janssen/Johnson & Johnson, Alector, Novo Nordisk, UCB Pharma, Novartis and ABScience; receipt of equipment, materials, drugs, medical writing, gifts, or other services from Meso Scale Discovery. EMA-U declares grants or contracts from Ministry of Science and Innovation (PID2019–111514RA-I00 and PID2023–15333620B-100), Alzheimer's, Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), the Spanish Ministry of Science and Innovation–State Research Agency (RYC2018–026053-I), and the European Social Fund, Research and Innovation Program of the Barcelona City Council, La Caixa Research (21s0906); is chair of the Reserve, Resilience And Protective Factors Professional Interest Area, International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association. LC declares grants or contracts from Alzheimer's Association (SG-21–814756-LatAm FINGERS, SG-21–715176-LATAM, and *SG-23*–1061591; all paid to her institution); support to attend the Alzheimer's Association International Conference (AAIC) 2024, as part of the Scientific Program Committee; is a chair of the World Young Leaders in dementia and declares participation in the WHO Neurology COVID-19 : Follow-up and Long-term Impact Working group. JF declares grants or contracts from Fondo de Investigaciones Sanitario Instituto de Salud Carlos III (Spain), National Institutes of Health (NIH) (USA), Generalitat de Catalunya, Fundació Tatiana Pérez de Guzmán el Buenon, Alzheimer's Association (USA), Brightfocus (USA), and Horizon 2020 (European Commission), all paid to his institution; consulting fees from Lundbeck, Roche, AC Immune; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Esteve, Biogen, Laboratorios Carnot, Adamed, Life Molecular Imaging, and Eli Lilly; holds a patent (WO2019175379) for A1 markers of synaptopathy neurodegenerative disease; participation on data safety monitoring boards or advisory boards for AC Immune, Alzheon, Roche, Eisa, Zambon, Eli Lilly, Ionis, and Perha; a leadership role for Spanish Neurological Society, T21 Research Society, Lumind Foundation, Jérôme-Lejeune Foundation, Alzheimer's Association, NIH (USA), Instituto de

Salud Carlos III (Spain); receipt of equipment, materials, drugs, medical writing, gifts or other services from Life Molecular Imaging. LTG declares grants or contracts from NIH, Rainwater Charitable Foundation, and Weill Neurosciences Hub, all paid to her institution; consulting fees from Guidepoint; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medscape, Otsuka Pharmaceutical Development & Commercialization; support for attending meetings and/or travel from Alzheimer Association and Rainwater Charitable Foundation; a leadership role in Global Brain Health institute. ZI declares grants or contracts from the National Institute on Aging, Canadian Institutes of Health Research, Canadian Consortium on Neurodegeneration in Aging, Brain Canada, Alzheimer's Drug Discovery Foundation, Weston Foundation, and Gordie Howe CARES (all paid to institution); consulting fees from Eisai, Eli Lilly, Novo Nordisk, Otsuka-Lundbeck, and Roche; participation on a data safety monitoring board for OCEANS study at Johns Hopkins and BioScel BXCL501; is chair of the Canadian Conference on Dementia and chair of the Canadian Consensus Conference on Diagnosis and Treatment of Dementia. SM declares grants or contracts from Nihon Medi-physics, Zieteo Medical, Ceremark Pharma; consulting fees from Hamamatsu Photonics; holding a patent on an Angiopep-2 Mediated Brain-Targeted PTX Conjugate for the Treatment Of Alzheimer's disease; having a leadership or fiduciary role in RSNA R&E Foundation Board of Trustees and SNMMI Value Initiative. RO has received research funding and support from European Research Council, ZonMw, Nederlandse Organisatie Voor Wetenschappelijk Onderzoek (Netherlands Organization for Scientific Research), National Institute of Health, Alzheimer Association, Alzheimer Nederland, Dioraphte Foundation, Cure Alzheimer's fund, Health~Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden, Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix, and Optina Diagnostics, all paid to his institution; declares consulting fees from Asceneuron, Bristol Myers Squibb, Biogen, all paid to his institution; has given lectures in symposia sponsored by GE Healthcare, all paid to his institution; is an editorial board member of Alzheimer's Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging. RCP declares grants or contracts from the National Institute on Aging and the National Institute of Neurological Disorders and Stroke (all paid to the institution); royalties from Oxford University Press and UpToDate; consulting fees from Roche, Genentech, Eli Lilly, Novo Nordisk, Nestle, Eisai and Novartis; payment or honoraria for educational activities from Medscape; participation on data safety monitoring boards or advisory boards for Genentech and Roche; and a leadership or fiduciary role in American Brain Foundation. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Eli Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD; is a cofounder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the University of Gothenburg Ventures Incubator Program without any products on the market; and is co-chair of the Global Biomarker Standardization Consortium and chair of the International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biomarkers for Neurodegenerative Diseases. BD declares grants or contracts from Roche, Fondation Merck-Avenir, Fondation Recherche Alzheimer, all paid to his institution; consulting fees from Qynapse, Aura; payment or honoraria for lecture from Schwabe Pharma; participation on a data safety monitoring board or advisory board for Barcelonaβeta Brain Research Center and Acumen.

Acknowledgments

Federico Massa, University of Genova, Italy, Angelo Bianchetti, Fondazione Teresa Camplani Domus Salutis Hospital, Brescia, Italy, and Nadji Abbas-Terki, Geneva, Switzerland, revised a late draft and provided useful criticism. Kristine Yaffe, University of California, USA, contributed useful comments. Estefania Vilarino, University of Geneva, Switzerland, helped collect data for figure 3 and tables S1 and S2. Jonathan Schott, University College London, UK, provided information on the use of plasma p-tau217 in the UK. We gratefully acknowledge the contribution by Camille Mercier, University of Geneva, who acted as editorial assistant and helped monitoring and collecting the scientific contributions and declarations of coauthors for all three papers of this Series.

References

1 Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. *Lancet* 2021; **397:** 1577–90.

2 Frisoni GB, Aho E, Brayne C, et al. Alzheimer's disease outlook: controversies and future directions. *Lancet* 2025; published online Sept 22. https://doi.org/10.1016/S0140-6736(25)01389-3.

3 Gauthier S, Rosa-Neto P, Morais JA, Webster C. World Alzheimer report 2021—journey through the diagnosis of dementia. London: Alzheimer's Disease International, 2021. https://www.alzint.org/resource/world-alzheimer-report-2021/ (accessed Aug 13, 2024).

4 Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. *JAMA* 2024; **332:** 1245–57.

5 Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. *J Neuropathol Exp Neurol* 2012; **71:** 266–73.

6 Vermunt L, Sikkes SAM, van den Hout A, et al, and the Alzheimer Disease Neuroimaging Initiative, and the AIBL Research Group, and the ICTUS/DSA study groups. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimers Dement* 2019; **15:** 888–98.

7 Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. *J Prev Alzheimers Dis* 2023; **10:** 362–77.

8 van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med* 2023; **388:** 9–21.

9 Sims JR, Zimmer JA, Evans CD, et al, and the TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA* 2023; **330:** 512–27.

10 Hansson O. Biomarkers for neurodegenerative diseases. *Nat Med* 2021; **27:** 954–63.

11 Hansson O, Seibyl J, Stomrud E, et al, and the Swedish BioFINDER study group, and the Alzheimer's Disease Neuroimaging Initiative. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimers Dement* 2018; **14:** 1470–81.

12 Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. *Alzheimers Dement* 2018; **14:** 1460–69.

13 Leitão MJ, Silva-Spínola A, Santana I, et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. *Alzheimers Res Ther* 2019; **11:** 91.

14 Fox NC, Belder C, Ballard C, et al. Treatment for Alzheimer's disease. *Lancet* 2025; published online Sept 22. https://doi.org/10.1016/S0140-6736(25)01329-7.

15 Petersen RC, Weintraub S, Sabbagh M, et al, and the Dementia Nomenclature Initiative. A new framework for dementia nomenclature. *JAMA Neurol* 2023; **80:** 1364–70.

16 Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis. *Neurologia* 2017; **32:** 523–32.

17 WHO. Dementia: key facts. March 31, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia (accessed Aug 11, 2025).

18 Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimers Dement* 2023; **19:** 658–70.

19 Hayes-Larson E, Ackley SF, Turney IC, La Joie R, Mayeda ER, Glymour MM, and the Alzheimer's Disease Neuroimaging Initiative. Considerations for use of blood-based biomarkers in epidemiologic dementia research. *Am J Epidemiol* 2024; **193:** 527–35.

20 Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, and the Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. *N Engl J Med* 2009; **360:** 2302–09.

21 Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. *Clin Epidemiol* 2014; **6:** 37–48.

22 Mielke MM, Aggarwal NT, Vila-Castelar C, et al, and the Diversity and Disparity Professional Interest Area Sex and Gender Special Interest Group. Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. *Alzheimers Dement* 2022; **18:** 2707–24.

23 Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. *Alzheimers Dement* 2016; **12:** 216–24.

24 Weiss J, Beydoun MA, Beydoun HA, et al. Pathways explaining racial/ethnic disparities in incident all-cause dementia among middle-aged US adults. *Alzheimers Dement* 2023; **19:** 4299–310.

25 Shiekh SI, Cadogan SL, Lin LY, Mathur R, Smeeth L, Warren-Gash C. Ethnic differences in dementia risk: a systematic review and meta-analysis. *J Alzheimers Dis* 2021; **80:** 337–55.

26 Pham TM, Petersen I, Walters K, et al. Trends in dementia diagnosis rates in UK ethnic groups: analysis of UK primary care data. *Clin Epidemiol* 2018; **10:** 949–60.

27 Gan J, Zeng Y, Huang G, et al. The updated prevalence and risk factors of dementia in old adults in China: a cross-sectional study. *J Alzheimers Dis* 2024; **102:** 1209–23.

28 Ng TP, Leong T, Chiam PC, Kua E-H. Ethnic variations in dementia: the contributions of cardiovascular, psychosocial and neuropsychological factors. *Dement Geriatr Cogn Disord* 2010; **29:** 131–38.

29 Suemoto CK, Leite REP, Paes VR, et al. Neuropathological lesions and cognitive abilities in black and white older adults in Brazil. *JAMA Netw Open* 2024; **7:** e2423377.

30 Arenson M, Bahorik A, Xia F, Peltz C, Cohen B, Yaffe K. Understanding racial disparities in dementia prevalence among veterans. *J Alzheimers Dis* 2024; **100:** 1075–82.

31 Luppa M, Luck T, Brähler E, König HH, Riedel-Heller SG. Prediction of institutionalisation in dementia. A systematic review. *Dement Geriatr Cogn Disord* 2008; **26:** 65–78.

32 Wu YT, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time—current evidence. *Nat Rev Neurol* 2017; **13:** 327–39.

33 Langa KM, Larson EB, Crimmins EM, et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. *JAMA Intern Med* 2017; **177:** 51–58.

34 Grasset L, Brayne C, Joly P, et al. Trends in dementia incidence: evolution over a 10-year period in France. *Alzheimers Dement* 2016; **12:** 272–80.

35 Grodstein F, Leurgans SE, Capuano AW, Schneider JA, Bennett DA. Trends in postmortem neurodegenerative and cerebrovascular neuropathologies over 25 years. *JAMA Neurol* 2023; **80:** 370–76.

36 Nichols E, Steinmetz JD, Vollset SE, et al, and the GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health* 2022; **7:** e105–25.

37 Chen Y, Bandosz P, Stoye G, et al. Dementia incidence trend in England and Wales, 2002-19, and projection for dementia burden to 2040: analysis of data from the English Longitudinal Study of Ageing. *Lancet Public Health* 2023; **8:** e859–67.

38 Bieger A, Brum WS, Borelli WV, et al, and the Alzheimer's Disease Neuroimaging Initiative. Influence of different diagnostic criteria on Alzheimer disease clinical research. *Neurology* 2024; **103:** e209753.

39 Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimers Dement* 2024; **20:** 5143–69.

40 Dubois B, Villain N, Schneider L, et al. Alzheimer disease as a clinical-biological construct—an International Working Group recommendation. *JAMA Neurol* 2024; **81:** 1304–11.

41 Mattke S, Hanson M. Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States. *Alzheimers Dement* 2022; **18:** 1071–74.

42 Mattke S, Tang Y, Hanson M. Expected wait times for access to a disease-modifying Alzheimer's treatment in England: a modelling study. *J Health Serv Res Policy* 2024; **29:** 69–75.

43 Mattke S, Tang Y, Hanson M, et al. Current capacity for diagnosing Alzheimer's disease in Germany and implications for wait times. *J Alzheimers Dis* 2024; **101:** 1249–59.

44 Mattke S, Gustavsson A, Jacobs L, et al. Estimates of current capacity for diagnosing Alzheimer's disease in Sweden and the need to expand specialist numbers. *J Prev Alzheimers Dis* 2024; **11:** 155–61.

45 Mattke S, Cho SK, Bittner T, Hlávka J, Hanson M. Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times. *Alzheimers Dement (Amst)* 2020; **12:** e12081.

46 Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the *Lancet* standing Commission. *Lancet* 2024; **404:** 572–628.

47 Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. A natural experiment on the effect of herpes zoster vaccination on dementia. *Nature* 2025; **641:** 438–46.

48 Howard C, Mukadam N, Hui EK, Livingston G. The effects of sleep duration on the risk of dementia incidence in short and long follow-up studies: a systematic review and meta-analysis. *Sleep Med* 2024; **124:** 522–30.

49 Pomirchy M, Bommer C, Pradella F, Michalik F, Peters R, Geldsetzer P. Herpes zoster vaccination and dementia occurrence. *JAMA* 2025; **333:** 2083–92.

50 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 2007; **25:** 1329–33.

51 Fortea J, Pegueroles J, Alcolea D, et al. Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease. *Nat Med* 2024; **30:** 2093.

52 Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. *JAMA Neurol* 2018; **75:** 970–79.

53 Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. *Nat Med* 2022; **28:** 2381–87.

54 Frisoni GB, Altomare D, Ribaldi F, et al. Dementia prevention in memory clinics: recommendations from the European task force for brain health services. *Lancet Reg Health Eur* 2023; **26:** 100576.

55 Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science* 1992; **256:** 184–85.

56 Beyreuther K, Masters CL. Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function. *Brain Pathol* 1991; **1:** 241–51.

57 Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. *Nat Neurosci* 2015; **18:** 800–06.

58 Frisoni GB, Altomare D, Thal DR, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. *Nat Rev Neurosci* 2022; **23:** 53–66.

59 Karran E, De Strooper B. The amyloid cascade hypothesis: are we poised for success or failure? *J Neurochem* 2016; **139** (suppl 2)**:** 237–52.

60 Jagust WJ, Teunissen CE, DeCarli C. The complex pathway between amyloid β and cognition: implications for therapy. *Lancet Neurol* 2023; **22:** 847–57.

61 Korczyn AD, Grinberg LT. Is Alzheimer disease a disease? *Nat Rev Neurol* 2024; **20:** 245–51.

62 Arenaza-Urquijo EM, Boyle R, Casaletto K, et al, and the Reserve, Resilience and Protective Factors Professional Interest Area, Sex and Gender Professional Interest area and the ADDRESS! Special Interest Group. Sex and gender differences in cognitive resilience to aging and Alzheimer's disease. *Alzheimers Dement* 2024; **20:** 5695–719.

63 Soldan A, Pettigrew C, Cai Q, et al, and the BIOCARD Research Team. Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease. *Neurobiol Aging* 2017; **60:** 164–72.

64 Stern Y. Cognitive reserve in ageing and Alzheimer's disease. *Lancet Neurol* 2012; **11:** 1006–12.

65 Canevelli M, Jackson-Tarlton C, Rockwood K. Frailty for neurologists: perspectives on how frailty influences care planning. *Lancet Neurol* 2024; **23:** 1147–57.

66 Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. *Neurology* 2018; **90:** 695–703.

67 Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* 2010; **9:** 119–28.

68 Lewis A, Gupta A, Oh I, et al. Association between socioeconomic factors, race, and use of a specialty memory clinic. *Neurology* 2023; **101:** e1424–33.

69 Patnode CD, Perdue LA, Rossom RC, et al. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2020; **323:** 764–85.

70 Tang-Wai DF, Smith EE, Bruneau MA, et al. CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales. *Alzheimers Dement (N Y)* 2020; **6:** e12057.

71 Verghese J, Chalmer R, Stimmel M, et al. Non-literacy biased, culturally fair cognitive detection tool in primary care patients with cognitive concerns: a randomized controlled trial. *Nat Med* 2024; **30:** 2356–61.

72 Atri A, Dickerson BC, Clevenger C, et al. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for primary care. *Alzheimers Dement* 2024; published online Dec 23. https://doi.org/10.1002/alz.14333.

73 Petrazzuoli F, Vinker S, Koskela TH, et al. Exploring dementia management attitudes in primary care: a key informant survey to primary care physicians in 25 European countries. *Int Psychogeriatr* 2017; **29:** 1413–23.

74 Finkel SI, Woodson C. History and physical examination of elderly patients with dementia. *Int Psychogeriatr* 1997; **9** (suppl 1)**:** 71–75.

75 Lopera F. Clinical history in the study of a patient with dementia. *Rev Neurol* 2001; **32:** 1187–91.

76 Rogers RL, Meyer JS. Computerized history and self-assessment questionnaire for diagnostic screening among patients with dementia. *J Am Geriatr Soc* 1988; **36:** 13–21.

77 Dewey ME, Copeland JR. Diagnosis of dementia from the history and aetiology schedule. *Int J Geriatr Psychiatry* 2001; **16:** 912–17.

78 Zhang J, Wang L, Deng X, et al. Five-minute cognitive test as a new quick screening of cognitive impairment in the elderly. *Aging Dis* 2019; **10:** 1258–69.

79 Brodaty H, Pond D, Kemp NM, et al. The GPCOG: a new screening test for dementia designed for general practice. *J Am Geriatr Soc* 2002; **50:** 530–34.

80 Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; **12:** 189–98.

81 Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; **53:** 695–99.

82 Creavin ST, Fish M, Lawton M, et al. A diagnostic test accuracy study investigating general practitioner clinical impression and brief cognitive assessments for dementia in primary care, compared to specialized assessment. *J Alzheimers Dis* 2023; **95:** 1189–200.

83 Vara A, Yates SJ, González Prieto CA, Rivera-Rodriguez CL, Cullum S. The Rowland Universal Dementia Assessment Scale (RUDAS) for the detection of dementia in a variety of healthcare settings. *Cochrane Database Syst Rev* 2022; **4:** CD014696.

84 Sabbagh MN, Boada M, Borson S, et al. Rationale for early diagnosis of mild cognitive impairment (MCI) supported by emerging digital technologies. *J Prev Alzheimers Dis* 2020; **7:** 158–64.

85 Montero-Odasso M, Pieruccini-Faria F, Ismail Z, et al. CCCDTD5 recommendations on early non cognitive markers of dementia: a Canadian consensus. *Alzheimers Dement (N Y)* 2020; **6:** e12068.

86 Frisoni GB, Festari C, Massa F, et al. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. *Lancet Neurol* 2024; **23:** 302–12.

87 de Wilde A, van Maurik IS, Kunneman M, et al. Alzheimer's biomarkers in daily practice (ABIDE) project: rationale and design. *Alzheimers Dement (Amst)* 2017; **6:** 143–51.

88 Vernooij MW, Pizzini FB, Schmidt R, et al. Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. *Neuroradiology* 2019; **61:** 633–42.

89 Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer's Disease. *Nat Rev Neurol* 2024; **20:** 426–39.

90 Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. *Lancet Neurol* 2020; **19:** 271–78.

91 Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface between delirium and dementia in elderly adults. *Lancet Neurol* 2015; **14:** 823–32.

92 Inouye SK. Delirium in older persons. *N Engl J Med* 2006; **354:** 1157–65.

93 Morandi A, Davis D, Bellelli G, et al. The diagnosis of delirium superimposed on dementia: an emerging challenge. *J Am Med Dir Assoc* 2017; **18:** 12–18.

94 Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. *Lancet* 2014; **383:** 911–22.

95 Leighton SP, Herron JW, Jackson E, Sheridan M, Deligianni F, Cavanagh J. Delirium and the risk of developing dementia: a cohort study of 12 949 patients. *J Neurol Neurosurg Psychiatry* 2022; **93:** 822–27.

96 Persico I, Cesari M, Morandi A, et al. Frailty and delirium in older adults: a systematic review and meta-analysis of the literature. *J Am Geriatr Soc* 2018; **66:** 2022–30.

97 Postema MC, Dubbelman MA, Claesen J, et al. Facilitating clinical use of the Amsterdam Instrumental Activities of Daily Living Questionnaire: normative data and a diagnostic cutoff value. *J Int Neuropsychol Soc* 2024; **30:** 615–20.

98 Sikkes SA, Pijnenburg YA, Knol DL, de Lange-de Klerk ES, Scheltens P, Uitdehaag BM. Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. *J Geriatr Psychiatry Neurol* 2013; **26:** 244–50.

99 Sikkes SA, Knol DL, Pijnenburg YA, de Lange-de Klerk ES, Uitdehaag BM, Scheltens P. Validation of the Amsterdam IADL Questionnaire, a new tool to measure instrumental activities of daily living in dementia. *Neuroepidemiology* 2013; **41:** 35–41.

100 Hermann P, Zerr I. Rapidly progressive dementias—aetiologies, diagnosis and management. *Nat Rev Neurol* 2022; **18:** 363–76.

101 Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. *Lancet Neurol* 2008; **7:** 246–55.

102 Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. *Lancet Neurol* 2022; **21:** 714–25.

103 Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological assessment, 5th edn. Oxford: Oxford University Press, 2012.

104 Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease? *Lancet Neurol* 2004; **3:** 246–48.

105 Wagner M, Wolf S, Reischies FM, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. *Neurology* 2012; **78:** 379–86.

106 Bergeron D, Gorno-Tempini ML, Rabinovici GD, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. *Ann Neurol* 2018; **84:** 729–40.

107 Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. *Brain* 2017; **140:** 3329–45.

108 Frisoni GB, Geroldi C, Beltramello A, et al. Radial width of the temporal horn: a sensitive measure in Alzheimer disease. *AJNR Am J Neuroradiol* 2002; **23:** 35–47.

109 Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. *Nat Rev Neurol* 2010; **6:** 67–77.

110 Wolk DA, Nelson PT, Apostolova L, et al. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. *Alzheimers Dement* 2025; **21:** e14202.

111 Lesman-Segev OH, La Joie R, Iaccarino L, et al. Diagnostic accuracy of amyloid versus 18 F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia. *Ann Neurol* 2021; **89:** 389–401.

112 Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. *J Neuropathol Exp Neurol* 1997; **56:** 1095–97.

113 Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimers Dement* 2012; **8:** 1–13.

114 Montine TJ, Phelps CH, Beach TG, et al, and the National Institute on Aging, and the Alzheimer's Association. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol* 2012; **123:** 1–11.

115 Palmqvist S, Mattsson N, Hansson O, and the Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. *Brain* 2016; **139:** 1226–36.

116 Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. *Neurology* 2019; **93:** e1647–59.

117 Janelidze S, Barthélemy NR, Salvadó G, et al. Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment. *JAMA Neurol* 2024; **81:** 947–57.

118 Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. *Brain* 2016; **139:** 1551–67.

119 Minoshima S, Drzezga AE, Barthel H, et al. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. *J Nucl Med* 2016; **57:** 1316–22.

120 Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement* 2015; **11:** 1–15.e4.

121 La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem [^{11}C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. *Alzheimers Dement* 2019; **15:** 205–16.

122 Therriault J, Vermeiren M, Servaes S, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. *JAMA Neurol* 2023; **80:** 188–99.

123 Barthélemy NR, Li Y, Joseph-Mathurin N, et al, and the Dominantly Inherited Alzheimer Network. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat Med* 2020; **26:** 398–407.

124 Barthélemy NR, Saef B, Li Y, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. *Nat Aging* 2023; **3:** 391–401.

125 Horie K, Salvadó G, Barthélemy NR, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. *Nat Med* 2023; **29:** 1954–63.

126 Vromen EM, de Boer SCM, Teunissen CE, et al, and the Alzheimer's Disease Neuroimaging Initiative. Biomarker A+T-: is this Alzheimer's disease or not? A combined CSF and pathology study. *Brain* 2023; **146:** 1166–74.

127 de Wilde A, Reimand J, Teunissen CE, et al. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. *Alzheimers Res Ther* 2019; **11:** 78.

128 Sala A, Nordberg A, Rodriguez-Vieitez E, and the Alzheimer's Disease Neuroimaging Initiative. Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity. *Mol Psychiatry* 2021; **26:** 5864–74.

129 Altomare D, Barkhof F, Caprioglio C, et al, and the Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Consortium. Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial. *JAMA Neurol* 2023; **80:** 548–57.

130 Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. *JAMA* 2019; **321:** 1286–94.

131 Hazan J, Wing M, Liu KY, Reeves S, Howard R. Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 2023; **94:** 113–20.

132 Siontis KC, Siontis GC, Contopoulos-Ioannidis DG, Ioannidis JP. Diagnostic tests often fail to lead to changes in patient outcomes. *J Clin Epidemiol* 2014; **67:** 612–21.

133 van Maurik IS, Broulikova HM, Mank A, et al. A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. *Alzheimers Dement* 2023; **19:** 2006–13.

134 Rabinovici GD, Carrillo MC, Apgar C, et al. Amyloid positron emission tomography and subsequent health care use among medicare beneficiaries with mild cognitive impairment or dementia. *JAMA Neurol* 2023; **80:** 1166–73.

135 Goedert M, Crowther RA, Scheres SHW, Spillantini MG. Tau and neurodegeneration. *Cytoskeleton* 2024; **81:** 95–102.

136 Josephs KA, Tosakulwong N, Weigand SD, et al. Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age-related tauopathy and Alzheimer's disease. *Sci Transl Med* 2024; **16:** eado8076.

137 Moon H, Chen X, and the Alzheimer's Disease Neuroimaging Initiative. Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD. *J Prev Alzheimers Dis* 2025; **12:** 100252.

138 Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. *JAMA* 2018; **320:** 1151–62.

139 Smith R, Cullen NC, Pichet Binette A, et al, and the Alzheimer's Disease Neuroimaging Initiative. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. *Alzheimers Dement* 2023; **19:** 2497–507.

140 Groot C, Smith R, Collij LE, et al. Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment. *JAMA Neurol* 2024; **81:** 845–56.

141 Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. *JAMA Neurol* 2021; **78:** 961–71.

142 Pontecorvo MJ, Devous MD, Kennedy I, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. *Brain* 2019; **142:** 1723–35.

143 Soleimani-Meigooni DN, Rabinovici GD. Tau PET visual reads: research and clinical applications and future directions. *J Nucl Med* 2023; **64:** 822–24.

144 Warmenhoven N, Salvadó G, Janelidze S, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. *Brain* 2025; **148:** 416–31.

145 Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. *Nat Med* 2022; **28:** 1398–405.

146 Janelidze S, Barthélemy NR, He Y, Bateman RJ, Hansson O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. *JAMA Neurol* 2023; **80:** 516–22.

147 Bornhorst JA, Lundgreen CS, Weigand SD, et al. Quantitative assessment of the effect of chronic kidney disease on plasma p-tau217 concentrations. *Neurology* 2025; **104:** e210287.

148 Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. *Nat Commun* 2020; **11:** 1683.

149 Devanarayan V, Doherty T, Charil A, et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. *Alzheimers Dement* 2024; **20:** 5617–28.

150 Salvadó G, Horie K, Barthélemy NR, et al. Disease staging of Alzheimer's disease using a CSF-based biomarker model. *Nat Aging* 2024; **4:** 694–708.

151 Li Y, Yen D, Hendrix RD, et al. Timing of biomarker changes in sporadic Alzheimer's disease in estimated years from symptom onset. *Ann Neurol* 2024; **95:** 951–65.

152 Barthélemy NR, Salvadó G, Schindler SE, et al. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. *Nat Med* 2024; **30:** 1085–95.

153 Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. *JAMA Neurol* 2024; **81:** 255–63.

154 Palmqvist S, Warmenhoven N, Anastasi F, et al. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform. *Nat Med* 2025; **31:** 2036–43.

155 Wang J, Huang S, Lan G, et al, and the Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN). Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts. *Alzheimers Dement* 2025; **21:** e70038.

156 Oh HS-H, Urey DY, Karlsson L, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease. *Nature Medicine* 2025; **31:** 1592–1603.

157 Taddei RN, Duff KE. Synapse vulnerability and resilience across the clinical spectrum of dementias. *Nat Rev Neurol*, 2025; **21:** 353–69.

158 DeCarli C, Frisoni GB, Clark CM, et al, and the Alzheimer's Disease Cooperative Study Group. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. *Arch Neurol* 2007; **64:** 108–15.

159 Molinder A, Ziegelitz D, Maier SE, Eckerström. Validity and reliability of the medial temporal lobe atrophy scale in a memory clinic population. *BMC Neurol* 2021; **21:** 289.

160 Pizzini FB, Ribaldi F, Natale V, et al. A visual scale to rate amygdalar atrophy on MRI. *Eur Radiol* 2024; **35**: 4246–56.

161 Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. *Neurology* 2020; **94:** 436–48.

162 Minoshima S, Cross D, Thientunyakit T, Foster NL, Drzezga A. 18F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with co-pathologies. *J Nucl Med* 2022; **63** (suppl 1)**:** S2–12.

163 McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology* 2017; **89:** 88–100.

164 Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. *Mov Disord* 2007; **22:** 1689–707, quiz 1837.

165 Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. *Lancet Neurol* 2022; **21:** 258–72.

166 Höglinger GU, Respondek G, Stamelou M, et al, and the Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. *Mov Disord* 2017; **32:** 853–64.

167 Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology* 2013; **80:** 496–503.

168 Khalil M, Teunissen CE, Lehmann S, et al. Neurofilaments as biomarkers in neurological disorders—towards clinical application. *Nat Rev Neurol* 2024; **20:** 269–87.

169 VandeVrede L, Cho H, Sanderson-Cimino M, et al. Detection of Alzheimer neuropathology in Alzheimer and non-Alzheimer clinical syndromes with blood-based biomarkers. *JAMA Neurol* 2025; **82:** 344–54.

170 Rajbanshi B, Prufer Q C Araujo I, VandeVrede L, et al, and the ALLFTD Consortium. Clinical and neuropathological associations of plasma $A\beta_{42}/A\beta_{40}$, p-tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders. *Alzheimers Dement (Amst)* 2025; **17:** e70078.

171 Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. *J Nucl Med* 2025; **21:** e14338.

172 Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimers Dement* 2018; **14:** 1505–21.

173 Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimers Dement* 2022; **18:** 2669–86.

174 Karanth S, Nelson PT, Katsumata Y, et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. *JAMA Neurol* 2020; **77:** 1299–307.

175 Bergeron D, Ossenkoppele R, Jr Laforce R. Evidence-based interpretation of amyloid-β PET results: a clinician's tool. *Alzheimer Dis Assoc Disord* 2018; **32:** 28–34.

176 Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. *Am J Geriatr Psychiatry* 2007; **15:** 84–87.

177 Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. *J Clin Psychiatry* 2004; **65** (suppl 11)**:** 16–22.

178 McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. *BMJ* 1992; **305:** 673–78.

179 Nielsen KD, Boenink M. Ambivalent anticipation: how people with Alzheimer's disease value diagnosis in current and envisioned future practices. *Sociol Health Illn* 2021; **43:** 510–27.

180 Alzheimer Europe. Alzheimer Europe position on the disclosure of the diagnosis to people with dementia and carers. Luxembourg: Alzheimer Europe, 2006. https://www.alzheimer-europe.org/sites/default/files/2021-10/AE%20Position%20-%20Disclosure%20of%20diagnosis%20-%20final%20version.pdf (accessed Nov 5, 2024).

181 Pittock RR, Aakre JA, Castillo AM, et al. Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. *Neurology* 2023; **101:** e1837–49.

182 Rosenberg A, Öhlund-Wistbacka U, Hall A, et al. β-amyloid, tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population. *Neurology* 2022; **99:** e2102–13.

183 US Food and Drug Administration. Laboratory developed tests. https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests (accessed Oct 1, 2024).

184 Mielke MM, Anderson M, Ashford JW, et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease. *Alzheimers Dement* 2024; **20:** 8216–24.

185 Therriault J, Janelidze S, Benedet AL, et al. Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability. *Nat Aging* 2024; **4:** 1529–37.

186 Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer report 2016—improving healthcare for people living with dementia; coverage, quality and costs now and in the future. London: Alzheimer's Disease International, 2016. https://www.alzint.org/u/WorldAlzheimerReport2016.pdf (accessed Oct 1, 2024).

187 Mielke MM, Anderson M, Ashford JW, et al. Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease. *Alzheimers Dement* 2024; **20:** 8209–15.

188 Karikari TK. Blood tests for Alzheimer's disease: increasing efforts to expand and diversify research participation is critical for widespread validation and acceptance. *J Alzheimers Dis* 2022; **90:** 967–74.

189 Wilkins CH, Windon CC, Dilworth-Anderson P, et al. Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) cohort study. *JAMA Neurol* 2022; **79:** 1139–47.

190 Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. *JAMA Neurol* 2019; **76:** 264–73.

191 Ramanan VK, Graff-Radford J, Syrjanen J, et al. Association of plasma biomarkers of Alzheimer disease with cognition and medical comorbidities in a biracial cohort. *Neurology* 2023; **101:** e1402–11.

192 Molina-Henry DP, Raman R, Liu A, et al. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. *Alzheimers Dement* 2024; **20:** 3827–38.

193 Xiong C, Luo J, Wolk DA, et al. Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals. *Nat Commun* 2024; **15:** 5539.

194 Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathol* 2021; **141:** 709–24.

195 Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med* 2020; **26:** 379–86.

196 La Joie R, Mundada NS, Blazhenetz G, et al. Quantitative amyloid-PET in real-world practice: lessons from the imaging dementia—evidence for amyloid scanning (IDEAS) study. *Alzheimers Dement* 2023; **19:** e082874.

197 Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. *Mol Neurodegener* 2021; **16:** 10.

198 Yun J, Shin D, Lee EH, et al. Temporal dynamics and biological variability of Alzheimer biomarkers. *JAMA Neurol* 2025; **82:** 384–96.

199 Leuzy A, Mattsson-Carlgren N, Cullen NC, et al. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. *Alzheimers Dement* 2023; **19:** 2994–3004.

200 Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk prediction, screening, and diagnosis. *BMJ* 2016; **353:** i3139.

201 Johnson KA, Minoshima S, Bohnen NI, et al, and the Alzheimer's Association, and the Society of Nuclear Medicine and Molecular Imaging, and the Amyloid Imaging Taskforce. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer's association. *Alzheimers Dement* 2013; **9:** e-1–16.